0000950123-23-011100.txt : 20231129 0000950123-23-011100.hdr.sgml : 20231129 20231129161928 ACCESSION NUMBER: 0000950123-23-011100 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20231129 DATE AS OF CHANGE: 20231129 EFFECTIVENESS DATE: 20231129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MAIA Biotechnology, Inc. CENTRAL INDEX KEY: 0001878313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-498379 FILM NUMBER: 231452469 BUSINESS ADDRESS: STREET 1: 444 WEST LAKE STREET, SUITE 1700 CITY: CHICAGO STATE: IL ZIP: 60606 BUSINESS PHONE: 312-416-8592 MAIL ADDRESS: STREET 1: 444 WEST LAKE STREET, SUITE 1700 CITY: CHICAGO STATE: IL ZIP: 60606 D 1 primary_doc.xml X0708 D LIVE 0001878313 MAIA Biotechnology, Inc. 444 West Lake Street Suite 1700 Chicago IL ILLINOIS 60606 312-416-8592 DELAWARE None None Corporation true Vlad Vitoc 444 West Lake Street Suite 1700 Chicago IL ILLINOIS 60606 Executive Officer Director Chief Executive Officer Jeffrey C Himmelreich 444 West Lake Street Suite 1700 Chicago IL ILLINOIS 60606 Executive Officer Head of Finance Jean-Manasse Theagene 444 West Lake Street Suite 1700 Chicago IL ILLINOIS 60606 Director Steven M Chaouki 444 West Lake Street Suite 1700 Chicago IL ILLINOIS 60606 Director Stan Smith 444 West Lake Street Suite 1700 Chicago IL ILLINOIS 60606 Director Sergei Gryaznov 444 West Lake Street Suite 1700 Chicago IL ILLINOIS 60606 Executive Officer Chief Scientific Officer Ramiro Guerrero 444 West Lake Street Suite 1700 Chicago IL ILLINOIS 60606 Director Ngar Yee Louie 444 West Lake Street Suite 1700 Chicago IL ILLINOIS 60606 Director Cristian Luput 444 West Lake Street Suite 1700 Chicago IL ILLINOIS 60606 Director Biotechnology Decline to Disclose 06b false 2023-11-15 false true true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 Park Avenue 4th Floor New York NY NEW YORK 10022 CA CALIFORNIA FL FLORIDA IL ILLINOIS NV NEVADA NJ NEW JERSEY NY NEW YORK TX TEXAS 4859092 4859092 0 The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors and placement agent in the private placement under Rule 506(b). false 3 280000 0 In connection with the Registered Direct Offering concurrent with the Private Placement, the Placement Agent received $280,000.07 in fees and warrants to purchase up to 169,697 shares of common stock exerciseable at $2.0625 per share. 0 false MAIA Biotechnology, Inc. /s/ Vlad Vitoc Vlad Vitoc Chief Executive Officer 2023-11-29